Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study
Open Access
- 25 January 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Urology and Nephrology
- Vol. 48 (5), 645-656
- https://doi.org/10.1007/s11255-015-1206-7
Abstract
Purpose To evaluate change in quality of life (QoL) and symptoms in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in conditions of current clinical practice. Methods Prospective, longitudinal, multicenter open-label study was carried out in urology outpatient clinics. Patients were ≥40 years of age with an International Prostate Symptom Score (IPSS) score ≥8. QoL and symptoms were measured at baseline and 6 months using the Benign Prostatic Hyperplasia Impact Index (BII) and the IPSS. Results 1713 patients were included for analysis. Mean (SD) IPSS and BII scores at baseline were 16.8 (5.4) and 6.8 (2.6), respectively. 8.9 % (n = 153) of study participants did not receive treatment (watchful waiting, WW), 70.3 % (n = 1204) were prescribed monotherapy (alpha-adrenergic blockers [AB]; phytotherapy [PT, of which 95.2 % was the hexanic extract of Serenoa repens, HESr]; or 5-alpha-reductase inhibitors [5ARI]), and 20.8 % (n = 356) received combined treatment (AB + 5ARI; AB + HESr; others). At 6 months, improvements in QoL were similar across the different medical treatment (MT) groups, both for monotherapy (AB: mean improvement [SD] of 2.4 points [2.4]; PT: 1.9 [2.4]; 5ARI: 2.5 [2.3]) and combined therapy (AB + 5ARI: 3.1 [2.9]; AB + PT: 3.1 [2.5]). There were no clinically significant differences between MT groups and all showed significant improvement over WW (p < 0.05). HESr showed similar efficacy to AB and 5ARI both as monotherapy and in combination with AB. Results on the IPSS were similar. Conclusions Improvements in QoL and symptoms were equivalent across the medical treatments most widely used in real-life practice to manage patients with moderate or severe LUTS. HESr showed an equivalent efficacy to AB and 5ARI with fewer side effects.Keywords
Funding Information
- Pierre Fabre Ibérica, S.A.
This publication has 48 references indexed in Scilit:
- Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal CellsInternational Journal of Molecular Sciences, 2013
- Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic reviewBJU International, 2012
- Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract SymptomsJAMA, 2011
- Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasiaWorld Journal of Urology, 2011
- Comparison of the Potency of Different Brands of Serenoa Repens Extract on 5α-Reductase Types I and II in Prostatic Co-Cultured Epithelial and Fibroblast CellsPharmacology, 2008
- Medical treatments for benign prostatic hyperplasia and sexual functionBJU International, 2008
- Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extractProstate Cancer and Prostatic Diseases, 2004
- Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients—PERMAL Study Subset AnalysisEuropean Urology, 2004
- Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in FranceProstate Cancer and Prostatic Diseases, 2001